Staff / TruthdigMay 25, 2016
Wall Street’s drive for profits is diminishing the benefits to society of new life-enhancing medications for which companies can charge patients hundreds of thousands of dollars per year. Dig deeper ( 2 Min. Read )
Staff / TruthdigFeb 5, 2016
Embattled Turing Pharmaceuticals CEO Martin Shkreli apparently did not show up for his hearing Thursday before the House Oversight Committee with a mind to shift public opinion in his favor or convince attendant legislators that he held anything resembling respect for the proceedings. Dig deeper ( 2 Min. Read )
Staff / TruthdigDec 18, 2015
The 32-year-old Turing Pharmaceuticals CEO and Wall Street player became a source of schadenfreude on a mass scale Thursday with the news that he had been arrested for securities fraud. Dig deeper ( 3 Min. Read )
Join our newsletterStay up to date with the latest from Truthdig. Join the Truthdig Newsletter for our latest publications.
Alexander Reed Kelly / TruthdigNov 26, 2015
The disreputable pharmaceutical boss has reneged on an agreement to lower the price of a medication he raised from $13.50 to $750 per pill. Dig deeper ( 1 Min. Read )
Staff / TruthdigNov 5, 2015
Republican Jason Chaffetz, chairman of the House Committee on Oversight and Governmental Reform, has been accused of protecting drug companies Valeant and Turing Pharmaceuticals from a congressional investigation into alleged price gouging. Dig deeper ( 2 Min. Read )
Kasia Anderson / TruthdigOct 5, 2015
Another drug company has joined the likes of the recently exposed Turing Pharmaceuticals by jacking up prices of life-sustaining meds on extremely short notice. Remember this name: Valeant Pharmaceuticals International. Dig deeper ( 1 Min. Read )
BLANKSep 27, 2015
The drug company CEO who announced a 5,000 percent increase in the price of a lifesaving drug was forced to back down after Twitter users, the industry and others exploded in outrage. We have three words for these sometimes rude commenters: Good for you. Dig deeper ( 3 Min. Read )
Staff / TruthdigSep 23, 2015
In case you hadn't heard, last month, Turing Pharmaceuticals CEO and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 per pill. Now he has a big public relations problem and a self-created health care crisis on his hands. Dig deeper ( 1 Min. Read )
Join our newsletterDon't miss out on the latest investigations, art critiques, provocative insights and original reporting from a progressive perspective — delivered straight to your inbox.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, please login or create a user profile.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, upgrade to supporter.